Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome
NCT05702905 on ClinicalTrials.gov · last registry update 2024-03-25
75 participants. Its estimated completion date, 31 December 2024, has passed with no update to the record. Primary outcome, as filed: Percentage change in bodyweight at 12 weeks for semaglutide versus metformin. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- UNKNOWN
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Peking University First Hospital
- Sponsor type
- Other
- Enrollment
- 75
- Started
- 2023-05-09
- Primary completion
- 2024-12-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage change in bodyweight at 12 weeks for semaglutide versus metformin
Conditions studied
PCOS (Polycystic Ovary Syndrome) · Semaglutide
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.